Vericel Corporation

Vericel Corporation is an American biopharmaceutical company focused on regenerative medicine and cell-based therapies. Its commercial portfolio is centered on treatments for specialized clinical needs, particularly severe burn injuries and cartilage damage in the knee. The company is associated with MACI, a cell-based product used for the repair of symptomatic full-thickness cartilage defects of the knee, and Epicel, a cultivated skin substitute used in the management of patients with deep dermal or full-thickness burns over a significant portion of the body. The business originated as Aastrom Bio, which was formed in 1989 in Ann Arbor, Michigan. Before it had a commercial product portfolio, the company was primarily associated with the development of cell-therapy and regenerative-medicine technologies. A major turning point occurred in the spring of 2014, when Aastrom acquired Sanofi's cell-therapy and regenerative-medicine business. That business had entered Sanofi's portfolio through Sanofi's 2011 acquisition of Genzyme. The transaction materially changed Aastrom's scale and operating profile: it brought established products and a revenue-generating commercial platform, while also increasing the company's employee count by approximately eight times according to the referenced account. In October 2014, Aastrom Bio adopted the Vericel name and moved its headquarters from Ann Arbor to Cambridge, Massachusetts. The rebranding reflected the company's evolution from an early-stage biotechnology enterprise into a commercial regenerative-medicine company with marketed cell-therapy products. The company is publicly traded under the ticker symbol VCEL. Vericel's positioning is specialist rather than mass-market. Its products depend on complex biological manufacturing, patient-specific or clinically specialized processes, and coordination with physicians and treatment centers. This creates a business model distinct from that of conventional pharmaceutical companies: product value is tied not only to the therapeutic concept but also to manufacturing reliability, clinical handling, regulatory compliance, and integration into specialist care pathways. The available reference material identifies the United States as its operating market and does not establish a broader international commercial footprint. The supplied reference material does not provide a detailed account of Vericel's later product launches, financial performance, executive history, acquisitions after 2014, or corporate strategy beyond the transformation associated with the Sanofi transaction and the subsequent rebrand. Accordingly, this dossier limits historical and business claims to information supported by the supplied sources.

Vericel traces its origin to Aastrom Bio, a biotechnology company formed in 1989 in Ann Arbor, Michigan. The early company focused on cell therapy and regenerative-medicine development but, according to the referenced history, did not initially have the established commercial products or revenue stream that later defined Vericel's operating model. The company's most consequential transformation took place in the spring of 2014. Aastrom Bio acquired Sanofi's cell-therapy and regenerative-medicine business. Sanofi had obtained that business through its acquisition of Genzyme in 2011. The transaction gave Aastrom access to marketed products and an existing commercial operation, changing the company from a development-oriented biotechnology business into a company with a revenue-generating portfolio. The referenced material also states that the acquisition increased Aastrom's employee count by approximately eight times, indicating a substantial expansion in organizational scale and operating responsibilities. The acquired portfolio included cell-based regenerative-medicine products associated with burn treatment and orthopedic care. Among the products identified in the available material are Epicel, a cultivated skin substitute used for certain patients with severe burns, and MACI, a cell-based product for repairing symptomatic cartilage defects of the knee. Their presence gave the company a commercial focus in specialized clinical markets rather than in broad primary-care pharmaceuticals. In October 2014, Aastrom Bio changed its corporate name to Vericel. At the same time, it relocated its headquarters from Ann Arbor, Michigan, to Cambridge, Massachusetts. The name change and relocation marked the formal consolidation of the company's new identity after the acquisition. Vericel subsequently operated as a publicly traded biopharmaceutical company under the ticker VCEL. The historical sources supplied for this dossier do not describe the company's complete subsequent development, including later management changes, product-generation history, detailed regulatory events, international expansion, financial results, or additional mergers and acquisitions. Those subjects therefore remain unexpanded here rather than being inferred from the company's general sector or product categories.

• 2014

  Aastrom acquires Sanofi's cell-therapy business

  [1]Vericelen.wikipedia.org

  In the spring of 2014, Aastrom Bio acquired Sanofi's cell-therapy and regenerative-medicine business, gaining marketed products, a revenue stream, and a substantially larger employee base.

• 2014

  Aastrom Bio becomes Vericel

  [1]Vericelen.wikipedia.org

  In October 2014, the company changed its name to Vericel and moved its headquarters from Ann Arbor, Michigan, to Cambridge, Massachusetts.

• 2011

  Sanofi acquires Genzyme

  [1]Vericelen.wikipedia.org

  Sanofi acquired Genzyme, bringing Genzyme's cell-therapy and regenerative-medicine business into Sanofi's corporate portfolio before its later sale to Aastrom Bio.

• 1989

  Aastrom Bio is formed

  [1]Vericelen.wikipedia.org

  Aastrom Bio was established in Ann Arbor, Michigan, as the predecessor company of Vericel.

Specialist regenerative medicine and cell therapy for orthopedic cartilage repair and severe-burn care.

• Cell-based cartilage repair

  MACI

  MACI is a cell-based regenerative-medicine product associated with repair of symptomatic full-thickness cartilage defects of the knee. It represents Vericel's orthopedic franchise and places the company in a specialized treatment area where product use is connected to orthopedic surgery and cartilage restoration rather than conventional systemic drug therapy. The supplied sources identify MACI as one of Vericel's principal commercial offerings but do not provide a detailed launch chronology or subsequent product-generation history.

• Cultivated skin substitute

  Epicel

  Epicel is a cultivated skin substitute used in the care of certain patients with severe burns, including deep dermal or full-thickness burns involving a substantial area of the body. The product reflects Vericel's focus on highly specialized cell-based treatment and burn-center care. Its commercial availability became part of Aastrom Bio's portfolio through the 2014 acquisition of Sanofi's cell-therapy and regenerative-medicine business.

• 2014

  Acquisition of Sanofi's cell-therapy and regenerative-medicine businessM&A

  Background

  Aastrom Bio had been a development-oriented biotechnology company without the established commercial platform later associated with Vericel. Sanofi's relevant business had previously come from Genzyme, which Sanofi acquired in 2011.

  Action taken

  In the spring of 2014, Aastrom Bio acquired Sanofi's cell-therapy and regenerative-medicine business, including products and operating capabilities.

  Aftermath

  The transaction provided marketed products and a revenue stream, expanded the workforce by approximately eight times according to the referenced history, and materially changed the company's scale and business profile.

  Source

• 2014

  Corporate rebrand and headquarters relocationStrategy

  Background

  Following the acquisition of Sanofi's cell-therapy and regenerative-medicine business, Aastrom Bio adopted a new corporate identity.

  Action taken

  In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan, to Cambridge, Massachusetts.

  Aftermath

  The change established Vericel as the company's public-facing corporate identity and accompanied its transition into a commercial regenerative-medicine business.

  Source

1. 1Vericelen.wikipedia.org
2. 2Vericel official websitevericel.com